Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid...

This study explored perceptions and initial experiences of abemaciclib, a CDK4/6 inhibitor, plus endocrine therapy (ET) as adjuvant targeted therapy for early breast cancer with high risk of recurrence (EBC). Early onset diarrhea is the most common side-effect, but its impact is often under-recognized and may affect treatment adherence.

Three serial interviews were conducted with five women with EBC recruited from four UK breast units. The baseline interview took place before the start of treatment, follow-up interviews 4 and 8 weeks later. Transcripts were analyzed following the framework approach to thematic analysis.

Diarrhea at follow-up was reported by 4 women, and in 3 this was the most bothersome symptom. It was usually managed by anti-diarrheal drugs and/or dietary modifications. One woman discontinued treatment due to its effect on day-to-day living. All patients said they adhered to treatment. Beliefs that the drug offered a lower risk of recurrence helped some to tolerate side-effects, alongside support from their clinical teams.

These initial findings showed that abemaciclib plus ET was generally manageable. Regular follow-up in this patient cohort could support early detection of symptoms. Further longitudinal real-world research into patients' experiences with abemaciclib plus ET for EBC is warranted.

NCT04584853 (06/07/2020).